Caliper Life Sciences Inc

Caliper Life Sciences — Merger or Acquisition (October 2011)

80 slides from Caliper Life Sciences's merger presentation, Oct 26, 2011

  1. Slide 1: A Revolution in Personalized Medicine - from Concept to Reality

    A Revolution in Personalized Medicine - from Concept to Reality Kevin Hrusovsky, CEO Caliper Life Sciences October 26, 2011

  2. Slide 2: Agenda

    Agenda Is Healthcare Sick? What is Working and What Isn’t? What’s Next in Innovation? Human – World iHealth Revolutionizing Medicine

  3. Slide 3: Are We Making Medical Progress?

    Lyman & Hirsch (2010), Personalized Medicine, pp223 40% decrease in smoking 50% decrease in infectious disease 30% decrease in infant mortality 30% decrease in premature cardiovascular deaths Are We Making Medical Progress?

  4. Slide 4: Despite These Advances, Life Expectancy is Slowing

    First time in 200 years, children’s life expectancy is shorter than parents Gains are Plateauing Despite These Advances, Life Expectancy is Slowing

  5. Slide 5: However Europeans and Women are Living Longer

    Lyman & Hirsch (2010), Personalized Medicine, pp223 However Europeans and Woman are Living Longer

  6. Slide 6: As Well as Centenarians Living Longer and Doing More

    "If you live to the age of a hundred you have it made, because very few people die past the age of a hundred.” - George Burns (1896-1996) Country 100 yrs + Per 100,000 China 17,800 1.3 Canada 3,795 11.5 UK 9,330 15 France 14,994 25 Japan 36,376 28 USA 95,548 31 Jaring Timmerman, 100 World record for

  7. Slide 7: So why is life expectancy slowing and predicted to decline?

    . So why is life expectancy slowing and predicted to decline?

  8. Slide 8: Obesity Increase Since 2000; 2/3 Adults are Overweight

    Costs doubled in U.S to $150B and projected to be $400B by 2020 Linked diseases: Diabetes, heart, kidney, cancer (NEJM, 2005; AHRQ, 2006; CBO, 2008; CDC, 2009) + = 37% Increase in Obesity Since 2000; 2/3 Adults are Overweight

  9. Slide 9: Alarming Obesity Trend and Negative Health Impact is Global

    http://www.prospectmagazine.co.uk/2010/07/a-pound-for-a-pound/ Alarming Obesity Trend and Negative Health Impact is Global

  10. Slide 10: Life Expectancy has Inverse Correlation with Energy Consumption

    (NEJM, 2005; AHRQ, 2006; CBO, 2008; CDC, 2009) Transporting 100 People Car Bus Bicycle http://www.howwedrive.com/2010/06/ Life Expectancy has Inverse Correlation with Energy Consumption

  11. Slide 11: How Has the National and Global Debt Crisis Contributed?

    http://thesocietypages.org/socimages/files/2009/03/debt2.png How Has the National and Global Debt Crisis Contributed?

  12. Slide 12: Consuming more Energy and Eating Bigger Meals

    http://www.jonathannicholas.com/2008/05/do-you-have-shrinking-square-feet/ Consuming more Energy and Eating Bigger Meals

  13. Slide 13: Despite Falling Life Expectancies, Expense Growing Rapidly

    Beyond Borders: Global biotechnology report 2011. Ernst & Young http://thesystemmd.com/?p=52 Despite Falling Life Expectancies, Expense Growing Rapidly

  14. Slide 14: Some Project Medicare Bankruptcy in Next 10-20 Years

    http://www.allhealth.org/sourcebookcontent.asp?CHID=123 Some Project Medicare Bankruptcy in Next 10-20 Years

  15. Slide 15: Extending Life Using Today's Medicine Doubles Costs

    $Billions 5% consume 50% and 65+ year olds spend 4x more Extending Life (77 to 84) Using Today’s Medicine, Doubles Costs

  16. Slide 16: A Revolution in Medicine is Needed to Extend Life Economically

    ~ ~ $2.5M A Revolution in Medicine is Needed to Extend Life Economically Expand life from 77 to 100 years “Sick care to Healthcare”

  17. Slide 17: While Healthcare may be Sick, There's a Clear Path

    While Healthcare may be Sick, There’s a Clear Path to 130

  18. Slide 18: If We All Live to 100, World Health Must Be Addressed

    7 Billion in 2011 11 Billion in 2020? However, If We All Live to 100, World Health Must Be Addressed

  19. Slide 19: What Isn't Working?

    ‘Y caligge_ What Isn’t Working?

  20. Slide 20: Are We Over-Testing / Treating?

    http://www.thedailybeast.com/newsweek/2011/08/14/some-medical-tests-procedures-do-more-harm-than-good.html Are We Over-Testing / Treating?

  21. Slide 21: Many Advances are Actually Harmful

    http://positivesideeffects.com/2011/07/09/medical-care-3rd-leading-cause-of-death/ Many “Advances” are Actually Harmful

  22. Slide 22: Some Suggest that CT Scans Cause Cancer

    http://ulasbagci.com/2011/02/25/ct-imaging-does-it-cause-to-cancer/ http://www.time.com/time/health/article/0,8599,1818520,00.html#ixzz1bFI06WcL Some Suggest that CT Scans Cause Cancer

  23. Slide 23: And Others Say Vitamin E Causes Prostate Cancer

    And Others Say Vitamins E causes Prostate Cancer

  24. Slide 24: Only 25% of Cancer Drugs Work; $1 Trillion Wasted Annually

    “If it were not for the great variability among individuals, medicine might well have been a science and not an art.” Sir William Osler (1849-1919) Only 25% of Cancer Drugs Work; $1 Trillion Wasted Annually

  25. Slide 25: PSA Test Contributes to the Problem

    http://online.wsj.com/article/SB10001424052970204294504576615572596987098.html PSA Test Contributes to the Problem

  26. Slide 26: Cancer Needs Biomarkers and a Precision Approach

    Drug Discovery Today, 2009 Top 15 Selling Oncology Drugs Generated $27B w/ 35% response 65% non response = $18B waste Toxicity = $20B Biomarkers Identify which patients benefit Targeted drugs to ‘right’ patients HER2 test for Herceptin KRAS test for Erbitux 80% response rate Cancer Needs Biomarkers

  27. Slide 27: What is Working?

    ‘Y college, What is Working?

  28. Slide 28: Cancer Survivors Doubled: Breast Cancer Earlier Detection

    # Cancer Survivors Doubled: Breast Cancer Earlier Detection

  29. Slide 29: We are Making Breakthroughs in Many Categories

    Hepatitis C Lupus Melanoma Cystic Fibrosis We are Making Breakthroughs in Many Categories

  30. Slide 30: Biomarkers for Personalized Medicine Are Revolutionary

    $2B $4B $5B $14B REQUIRES a biomarker test for 20 approved drugs RECOMMENDS a biomarker test for 102 approved drugs Updated: October 4, 2011 Biomarkers for Personalized Medicine Are Revolutionary

  31. Slide 31: An Incredible Recent Example – Metastatic Melanoma Cure

    Plexxikon / Roche: 81% metastatic melanoma patients with a BRAF (V600E ) activating mutation responded to treatment with PLX4032, a highly selective kinase inhibitor. “These results represent a major breakthrough and provide proof that the treatment of metastatic melanoma can be individualized for a

  32. Slide 32: Molecular Testing is Replacing Invasive Amniocentesis

    Molecular Testing is Replacing Invasive Amniocentesis

  33. Slide 33: Powerful Boutique Firms are Emerging: 23andMe

    Powerful Boutique Firms are Emerging: 23andMe

  34. Slide 34: N of One: Realizing Personalized Medicine

    N of One: Realizing Personalized Medicine

  35. Slide 35: Biomarker Assessment for Personalized Treatment

    Biomarker Assessment for Personalized Treatment

  36. Slide 36: Websites are Beginning to Deal with Holistic Medicine

    http://www.informationisbeautiful.net/play/snake-oil-supplements/ And Websites are Beginning to Deal with Holistic Medicine

  37. Slide 37: Site Directs to Scientific Literature

    Site Directs to Scientific Literature

  38. Slide 38: What's Next in Innovation? Revolutionizing Medicine

    What’s Next in Innovation? Revolutionizing Medicine

  39. Slide 39: Caliper's Original View of the Drug Discovery Value Chain

    Caliper’s Original View of the Drug Discovery Value Chain Industry Paradigms Reduce time to failure (HTS) Accelerate experimentation cycles Reduce false positives/negatives Improve productivity Design Compounds Synthesize Compounds Biological Assays Analyze Data Day 2 Day 1 Traditional Process: $1B

  40. Slide 40: IIH Bridge Yields Translational Medicine

    Strategic Goal DNA, RNA, Protein Cells Mice Tissue Human Preclinical Clinical In vitro In vivo COST OF TESTING DATA QUALITY IIH Bridge Yields Translational Medicine Improve predictive power of each phase of experimentation

  41. Slide 41: Caliper & PKI Platforms for Translational Medicine

    Strategic Goal DNA, RNA, Protein Cells Mice Tissue Human Preclinical Clinical In vitro In vivo DATA QUALITY Caliper & PKI Platforms for Translational Medicine VisEn, IVIS Maestro, Vectra LabChip, Zephyr, Janus, Envision Operetta (HCS) Enspire, Automation, cell plate Instruments Reagents & Services N

  42. Slide 42: Caliper Bridging Strategy

    in vitro in vivo Pre -clinical Clinical Clinical Pre-clinical Pre -clinical Clinical in vitro in vivo Operetta AlphaLISA Radiology business TSA LabChip CRi VisEn IVIS Prenatal and neonatal screening Molecular Dx – DXI/DXII Circulating tumor cells Clinical and companion diagnostics Molecular and Imag

  43. Slide 43: Our Strategic Roadmap: Invest in Six Key Trends

    Biotherapeutics: Targeted Discovery Cellular Systems Biomarkers Genomic Analysis: Treatment Imaging & Pathology Our Strategic Roadmap: Invest in Six Key Trends Six disruptive, enabling technologies to revolutionize medicine Detection

  44. Slide 44: Next Gen Sequencing is Changing Disease Understanding

    Four-year old Nicholas Volker was wasting away, despite 100+ surgeries to repair multiple intestinal fistulas Clinicians could not diagnose the problem Nicholas’ life was saved by whole-exome sequencing: Revealed mutation in XIAP (a mutation on the X chromosome) Once defect known, treated by a bone

  45. Slide 45: And Impacting Childhood Disease Detection

    And Impacting Childhood Disease Detection

  46. Slide 46: But is Being Bottlenecked by Sample Prep and Informatics

    But is Being Bottlenecked by Sample Prep and Informatics sample prep & Informatics

  47. Slide 47: Caliper is Collaborating to Address these Bottlenecks

    Caliper is Collaborating to Address these Bottlenecks

  48. Slide 48: The Genetic Testing Landscape Today is Complicated

    QPCR End Point PCR Next Gen Sequencing Informatics Sample Prep Detection The Genetic Testing Landscape Today is Complicated

  49. Slide 49: Caliper is Working to Simplify and Integrate Workflows

    QPCR End Point PCR Next Gen Sequencing Informatics Sample Prep Detection Caliper is Working to Simplify and Integrate Workflows

  50. Slide 50: The Power of Multiplexing is Substantial

    The Power of Multiplexing is Substantial

  51. Slide 51: Traditional Pathology is Prone To Error

    Single breast cancer marker analysis is “prone to error” 90,000 Ductal Carcinoma in situ (D.C.I.S.) cases misdiagnosed Her2 IHC status alone: 22% false positives and 9% false negatives ER / PR status alone – 10-20% false positive Multiple biomarker classification for breast cancer prognosis / treatm

  52. Slide 52: Better Technologies are Enabling More Accurate Results

    Conventional Color Image Spectral signal isolation Pattern-recognition image analysis Multiplexed pAKT, pERK, & pS6 (plus DAPI) – Integrated Reagent Kit Capability (CST, HistoRx) Signal Composite Image Analyzed Image VectraTM Per-cell multi-parameter data Autofluorescence removed But Better Technolo

  53. Slide 53: Enabling More Multiplexing: More from Less, Faster

    - Saves precious time - Saves previous sample, if multiplexing* is used - More cost-effective to run all three tests up front Horn & Pao (2009) JCO, v.26, pp. 4232-4234; Bunn & Doebele (2011) JCO, v.29, pp.1-3 Serial Molecular Testing (Reflex approach) Simultaneous Molecular Testing And Enabling Mor

  54. Slide 54: Enabling Broad Characterization of CTCs

    Yu M et al. JCB 2011;192:373-382 LabChip GX/DX Nuance/ Vectra Labchip XT Enabling Broad Characterization of CTCs “One/billion”

  55. Slide 55: More from Less at MGH: First 6-Label, In-chip Analysis of CTCs

    MSI Keratin Signaling 1 Signaling 2 Phalloidin Ki67 DAPI More from Less at MGH: First 6-Label, In-chip Analysis of CTCs More from less, faster, with higher fidelity

  56. Slide 56: Multiplexing Enablement Collaborators

    Principle Invest. Institution Multiplexing Enablement Massimo Loda Dana Farber Prostate cancer stratification (PI3K pathway) Kent Osborne Baylor Breast cancer stratification (multiplexed Her1/2/3) David Rimm Yale (HistoRX founder) Breast cancer aspirate prognostic, trainable pattern recognition Gust

  57. Slide 57: Stem Cells & Regenerative Medicine

    A breakthrough in medical akin to antibiotics and vaccines? Converting somatic cells into iPSCs is a cellular breakthrough iPSCs are better: Technically much easier Cells are patient-specific Avoids immune rejection Eliminates ethical dilemma * Takahashi & Yamanaka pioneered the development of iP As

  58. Slide 58: Largest Library of In-Vivo Imaging Publications

    Largest Library of In-Vivo Imaging Publications Cumulative Publications And Researchers Are Finding Novel Applications

  59. Slide 59: Vaccines are Preventing Disease

    Children will be treated with specific vaccines based on genetic profile Smallpox is eradicated! Polio reduced from 400,000 cases in 1980 to 1600 in 2009 Guinea Worm disease reduced from 890,000 in 1989 to 3,200 in 2000 Is cancer the next disease to be eradicated? Merck – cervical cancer; Dendrion –

  60. Slide 60: While Biotherapeutics are Transforming Treatment Regimens

    Transforming the Body’s Ability to Fight Disease LabChip GXII While Biotherapeutics are Transforming Treatment Regimens

  61. Slide 61: Targeted Small Molecules are Making a Major Impact

    And Targeted Small Molecules are Making a Major Impact

  62. Slide 62: More from Less, Faster and Better: Products

    Minimizes sample yield loss Reduces PCR biases High quality results from smaller samples Sciclone® G3 / Zephyr® LabChip® GX – XT – DS – Dx Critical IP for NGS platforms Products More from Less, Faster and Better Distinguishes heterogeneity / morphology Accelerated small animal trials IVIS® Lumina II

  63. Slide 63: Caliper's External Collaborations Drive Innovation

    Genomic Analysis Imaging & Pathology Biomarkers & CDx Biotherapeutics Targeted Small Mol Discovery Cellular Systems Detection Treatment Emerging R&D investment opportunity Caliper’s External Collaborations Drive Innovation

  64. Slide 64: Human — World iHealth

    YF Caliper Human — World iHealth

  65. Slide 65: Enabling Platforms for World Health

    Biotherapeutics: Targeted Small Molecule Discovery Cellular Systems Biomarkers & CDx Genomic Analysis: Detection Treatment Imaging & Pathology Services, Reagents & Informatics Detection & Probes Diagnostics Channel Readers & Reagents HCS Imaging & consumables QC Assays Informatics World Health Enabl

  66. Slide 66: World Health

    World Health Cancer Personalized Medicine Fitness Climate Clean Water Translational Medicine Carcinogens Mental Health Regenerative Medicine Pollution

  67. Slide 67: World Health: Environmental Impact

    World Health 13 million deaths/year saved by clean environments 4 million child deaths/yr saved by clean water & air 1/3 of all children’s disease is environmental In the least developed countries, 1/3 of death and disease is a direct result of environmental causes Better environmental could prevent

  68. Slide 68: Improving iHealth one app at a time

    Food Pathogens Chemicals Water Safety Pollution Biomarkers Side Effects Calories Dosages Symptoms Exercise Improving iHealth one app at a time Medicines Air Quality Human Health World Health

  69. Slide 69: Culture is a Critical Component to Enable a Revolution

    State of Healthcare Triple Crown Focus Revolutionizing Medicine Culture is a Critical Component to Enable a Revolution

  70. Slide 70: Common Greater Purpose

    Improve the quality and length of life for all mankind by commercializing disruptive technologies that enable a revolution in personalized healthcare. Common Greater Purpose

  71. Slide 71: Culture; High Performance Teams Inspiring Innovation & Growth

    Culture; High Performance Teams Inspiring Innovation & Growth

  72. Slide 72: Innovation Reading List & Resources

    Open our Minds and Learn from Others Steal Shamelessly Best Practices Secretariat Invictus Coach Carter Remember the Titans Apollo 13 Rudy Long Life Resources http://www.livingto100.com/ http://www.realage.com http://www.healthstatus.com/ http://www.personalgenomes.org/ http://www.webmd.com/ http://

  73. Slide 73: Stakeholder Input Drives Strategic Decisions

    Stakeholder Input Drives Strategic Decisions Kathryn Tunstall Caliper BOD Bob Burt Pfizer BOD Ross Muken Deutsche Bank

  74. Slide 74: One Vision One Team – ALL IN

    One Vision One Team – ALL IN We have an unprecedented opportunity to impact patients We are responsible for our mindset, behavior and unconquerable spirit We must be masters of our fate to unleash this “Tremendous Machine” What are the ingredients for Greatness? - Inspire yourself and the great team

  75. Slide 75: Key Stakeholders: Opportunity to Leverage Momentum

    Key Stakeholders: Opportunity to Leverage Momentum all are “bought in” to Caliper vision Strategic Customers: Pfizer, J&J, BMS, Amgen, Abbott, Novartis, Broad, Stanford, Miami, Core genome centers Partnerships with NimbleGen, NuGEN, Illumina, HistoRx, CST, Seegene, Access Genetics, Dupont, etc. Inve

  76. Slide 76: Collaborations Drive Reinvented IRB Processes

    Bringing technology, discovery, and development closer to patients IRB re-invention Collaborations Drive Reinvented IRB Processes

  77. Slide 77: Caliper Owners Group is Critical Feedback Forum

    High profile keynote speakers Six themes, 100 speakers, 1000 attendees Game changing talks and inputs 27 20 11 16 17 12 Caliper Owners Group is Critical Feedback Forum

  78. Slide 78: In Loving Memory

    Willard Scott Rick’s Mom, Eva Bernal 104 years! Passed in January 2009 In Loving Memory My Mom, Eileen Hrusovsky 81 years! BUCKEYE Grandma Passed in July’07 In Loving Memory Randy Pausch Passed in 2009 Andrew McDonough B+ Foundation Passed in 2009 Elliot Parish “Elliot’s Machine” Passed in 2011 Stev

  79. Slide 79: Thank You! Acknowledgements

    Thank You! Acknowledgements: Caliper Customers and Collaborators Caliper and PerkinElmer Team: Irene Rombel, Ph.D., Mark Roskey, Ph.D., Nate Cosper, Ph.D., Alan Fletcher, Ph.D., Rob Friel, Isaac Meek and Cathy Portanova

  80. Slide 80: VW Cal | Per ces

    eA, . VW Cal | Per ces

Caliper Life Sciences — Merger or Acquisition (October 2011) on 6ix